Crispr Therapeutics shares tumble after significant earnings miss
CAMPBELL, CA—Denny Laurence, the Chief Legal Officer of 8x8 Inc . (NASDAQ:EGHT), recently sold 10,000 shares of the company’s common stock. The shares were sold at a price of $3.00 each, amounting to a total transaction value of $30,000. Following this sale, Laurence holds 233,791 shares in the company.
The shares sold were part of Laurence’s direct ownership in 8x8 Inc. It’s noteworthy that the shares owned after the transaction include 10,000 shares purchased on February 9, 2025, through the company’s Employee Stock Purchase Plan (ESPP).
In other recent news, 8x8 Inc. has reported its third-quarter fiscal year 2025 results, which aligned with consensus estimates for revenue and earnings per share. Needham analysts have responded by raising the stock price target to $3.50 and maintaining a Buy rating, despite the company’s slight lowering of its full-year guidance due to anticipated foreign exchange headwinds. On the other hand, Mizuho (NYSE:MFG) Securities has downgraded 8x8’s stock from Neutral to Underperform and lowered its price target to $2.50, citing concerns over the company’s revenue growth and profitability.
In a series of recent developments, 8x8 has made significant changes to its leadership team. The company has appointed Joel Neeb as Chief Transformation and Business Operations Officer, a role in which he will oversee the alignment of the company’s customer experience transformation and strategic initiatives. Additionally, John Pagliuca, a seasoned executive with over two decades of leadership experience within the software and SaaS industries, has been added to 8x8’s Board of Directors.
These developments reflect 8x8’s ongoing efforts to strengthen its leadership team and strategic direction, even as it faces challenges in its revenue growth and profitability. The company’s management has emphasized that platform bundling is now the primary go-to-market strategy and that debt servicing remains a key focus for capital allocation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.